Overseas business expansion focused on Asia
First written in FY2021. 8 of 17 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-08-06.
3 other companies' latest entry also says "Advanced".
- FY2026RaisedAnnual report
「In Singapore, where the expected market size is 6,000 cases per year, and Indonesia, where it is 3,000 cases per year, we aim to eventually secure a 50% market share.」
The target regions and target level have expanded from the previous goal of a 20% market share in Singapore to a plan targeting a 50% market share in Singapore and Indonesia in the future. - FY2026AdvancedAnnual report
「STEMCELL INNOVATIONS PTE. LTD.'s CPC (Cell Processing Center) and CCC (Cell Cryopreservation Center) are scheduled for completion in June 2026, followed by the acquisition of a business license from MOH (Ministry of Health) and the commencement of operations in the middle of the fiscal year ending March 2027.」
Construction of the CPC and CCC in Singapore is under way, and the application for a business license from MOH has been completed. The planned start of operations in the middle of the fiscal year ending March 2027 was also presented. - FY2026-H1AdvancedAnnual report
「In Singapore, where the storage rate relative to the number of births is approximately 20%, we aim to capture a 20% market share within 3 to 5 years. In the Jakarta area, we will seek to capitalize on the rapidly growing market by increasing brand awareness and expanding market share at an early stage. We also have global expansion, including India and the Middle East, in view for the future.」
The existing ASEAN expansion policy has taken concrete shape as a plan to target a 20% market share in Singapore within 3 to 5 years, expand into the Jakarta area, and pursue future global expansion including India and the Middle East. - FY2026-H1AdvancedAnnual report
「Subsequently, the company carried out a capital increase in August 2025 under a joint venture agreement with the family office of the founding family of Sinar Mas Group, one of Indonesia's largest conglomerates, increasing capital to SGD 7,000,000. The company's ownership ratio is 50%. Preparations for commencing operations also entered full swing, and as the importance of the business increased, the company made the entity a consolidated subsidiary from the current interim consolidated accounting period.」
The ASEAN expansion has taken concrete shape through a capital increase for the Singapore joint venture, capital of SGD 7,000,000, a 50% ownership ratio, and the entity's inclusion as a consolidated subsidiary. - FY2025RaisedAnnual report
「We will expand our business in the Southeast Asian (SEA) market. We aim to establish a revenue base, targeting annual sales of approximately ¥1 billion in Singapore and ¥3 billion to ¥5 billion across Southeast Asia within the next 3 to 5 years.」
After establishing a regional headquarters in Singapore in November 2024, the company set new targets of approximately ¥1 billion in annual sales in Singapore and ¥3 billion to ¥5 billion across SEA within the next 3 to 5 years. - FY2025-H1AdvancedAnnual report
「The company is currently focusing on expanding its business in Southeast Asia (ASEAN). The region has more than 10 million births annually, is expected to surpass Japan's GDP in 2027, and is expected to see substantial growth in the cell banking market. We are first preparing to establish a regional headquarters (holding company) in Singapore, with completion scheduled by November, and ultimately aim to establish operating companies in Singapore, Vietnam, Indonesia and other ASEAN countries under its umbrella to develop new markets.」
The company's existing policy for expansion in Asia has taken concrete shape in ASEAN. Against the backdrop of more than 10 million births annually and the expected economic scale in 2027, preparations are under way to establish a regional headquarters in Singapore, with completion scheduled by November. Plans were also presented to establish operating companies in Vietnam, Indonesia and other countries in the future. - FY2024-Q1RestatedAnnual report
「Interactions with overseas companies that had temporarily stopped during the COVID-19 pandemic are gradually resuming, and we will once again pursue overseas expansion, particularly in Asia.」
The company continues its policy of renewed efforts toward overseas expansion, particularly in Asia, in light of the resumption of interactions with overseas companies. No completed partnerships or market entries were reported. - FY2023RestatedAnnual report
「Interactions with overseas companies that had temporarily stopped during the COVID-19 pandemic are gradually resuming, and we will once again pursue overseas expansion, particularly in Asia.」
A policy of renewed efforts toward overseas expansion, particularly in Asia, was presented in light of the resumption of interactions, but no completed partnerships or market entries were reported. - FY2022RestatedAnnual report
「We will also conduct market research and pursue partnerships with local medical institutions and other parties with a view to expanding into countries, particularly in Asia, where the cell banking business remains underdeveloped.」
The company continues to pursue its policy of expanding overseas, particularly in Asia, through market research and partnerships with local medical institutions and others. - FY2021First statedAnnual report
「With a view to expanding into countries, particularly in Asia, where the cell banking business remains underdeveloped, we will conduct market research and pursue partnerships with local medical institutions and other parties.」
The company plans to expand overseas through market research and partnerships with local medical institutions.